Real-world data in life sciences is doing what once seemed impossible: challenging the dominance of traditional clinical trials. For decades, clinical trials have been the gold standard in life sciences research. And it makes sense: they’re rigorously controlled and designed to ensure that the true effects of drugs are being measured. But the real world…

Real-World Data: The Cornerstone of Life Science Consulting Life sciences are at an inflection point. As pressure mounts to develop therapies faster, prove real-world value to payers, and personalize interventions, traditional data sources are hitting their limits. Real-world data (RWD), particularly claims data, has emerged as a critical lever across the product lifecycle. For consultancies,…

Why Real-World Evidence Matters Beyond Clinical Trials Market access has never been more complex than it is right now. In a world where payers are tightening the purse strings and every therapeutic area feels like a battleground, just getting a therapy onto formulary, or getting a diagnostic test approved isn’t enough. You need to prove…

The Old Operating System Is Crashing Let’s be honest: pharma’s old operating system is starting to show its age. The traditional model – built around blockbuster drugs, top-down messaging and rigid pipelines – is crashing under the weight of modern complexity. Shareholder returns are sluggish. CEOs are second-guessing legacy bets. The pressure to demonstrate real…

Digital health solutions are increasingly common in healthcare, with over
300,000 health apps available and more than half of U.S. adults using
digital health tools.

Gram-negative bacteria. The very name can send shivers down the spines of healthcare professionals. These microorganisms, characterized by their complex cell wall structure, are increasingly developing resistance to even our strongest antibiotics.  If bacterial infections in general are a concern, gram-negative bacteria are particularly challenging – since even minor infections can become life-threatening when they…

For all the buzz around the Inflation Reduction Act (IRA), opinions on its impact are sharply divided – especially in the life sciences sector. Critics argue that the IRA’s drug pricing provisions, particularly Medicare price negotiation, will stifle innovation by reducing incentives for pharmaceutical companies to invest in research and development.  But these concerns don’t…